Zhu Yuan, Yin Chao, Wang Yeqi
School of Sports and Health, Nanjing Sport Institute, Nanjing 210014, China.
Taian Institute for Food and Drug Control, Taian 271000, China.
Bioengineering (Basel). 2024 Oct 16;11(10):1033. doi: 10.3390/bioengineering11101033.
Atherosclerosis, as the main root cause, makes cardiovascular diseases (CVDs) a substantial worldwide health concern. Inflammation and disrupted cholesterol metabolism are the primary clinical risk elements contributing to the onset of atherosclerosis. Few works exist on the improvement effect of gut microbiota on atherosclerosis. One specific probiotic strain, Enterococcus faecium NCIMB11508, has shown promise in mitigating inflammation. Consequently, it is critical to investigate its potential in reducing the progression of atherosclerosis. In our study, we administered NCIMB11508 orally to ApoE mice, resulting in a decrease in the formation of atherosclerotic lesions. Additionally, it demonstrated the ability to lower the inflammatory factor levels both in the aorta and blood serum while maintaining the integrity of the small intestine against lipopolysaccharides. Moreover, NCIMB11508 had a beneficial impact on the gut microbiota composition by increasing the levels of short-chain fatty acids (SCFAs), which in turn helped to reduce inflammation and protect the intestine. The probiotic NCIMB11508, according to our research, has a definitive capacity to prevent atherosclerosis progression by beneficially altering the SCFA composition in the gut microbiota of ApoE mice.
动脉粥样硬化作为主要根源，使心血管疾病成为全球重大的健康问题。炎症和胆固醇代谢紊乱是导致动脉粥样硬化发病的主要临床风险因素。关于肠道微生物群对动脉粥样硬化的改善作用的研究较少。一种特定的益生菌菌株，屎肠球菌NCIMB11508，已显示出减轻炎症的潜力。因此，研究其在减缓动脉粥样硬化进展方面的潜力至关重要。在我们的研究中，我们给载脂蛋白E基因敲除（ApoE）小鼠口服NCIMB11508，导致动脉粥样硬化病变形成减少。此外，它还表现出能够降低主动脉和血清中的炎症因子水平，同时维持小肠对脂多糖的完整性。此外，NCIMB11508通过增加短链脂肪酸（SCFAs）水平对肠道微生物群组成产生有益影响，这反过来有助于减轻炎症并保护肠道。根据我们的研究，益生菌NCIMB11508具有通过有益地改变ApoE小鼠肠道微生物群中的SCFA组成来预防动脉粥样硬化进展的明确能力。
